With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli ... Related: Ozempic ...

For example, a starter dose of Novo’s Ozempic is 25 milligrams ... Hims' business has grown significantly, as have other ...

“Given the ongoing shortages of branded medications such as Ozempic and Wegovy ... members have expressed consideration of a compounded GLP-1 for their journey.3 That’s why, after months ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

It can be harder to lose weight after a certain age, which is why GLP-1 medications can be incredibly useful. That's where ...

“Given the ongoing shortages of branded medications such as Ozempic and Wegovy ... which is why anyone prescribed a compounded GLP-1, receives step-by-step guidance on how to use the medication safely ...